Talk:Pexastimogene devacirepvec

This is the talk page for discussing improvements to the Pexastimogene devacirepvec article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Medicine: Hematology-oncology Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.
	This article is supported by the Hematology-oncology task force.

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

We should probably move/rename this to Pexa-vec soon

Pexa-vec ? or would pexastimogene devacirepvec be the INN ? - Rod57 (talk) 09:35, 10 May 2013 (UTC)[reply]

You are right, this page will need moving to pexastimogene devacirepvec, can create a redirect to there from Pexa-vec, this would be in-keeping with talimogene laherparepvec. Viraltonic (talk) 11:12, 10 May 2013 (UTC)[reply]

Done - Rod57 (talk) 18:45, 14 October 2016 (UTC)[reply]

Out of date

Article gives status as of Aug 2011 but the phase III trial failed its primary endpoint in 2013 and the company website gives the March 2014 development plan. - Rod57 (talk) 23:04, 14 November 2014 (UTC)[reply]

Website also says "A Phase 2b study (TRAVERSE) was also initiated in HCC patients whose disease had progressed on or following treatment with sorafenib or who could not tolerate that treatment. In September 2013, Transgene announced that the TRAVERSE study did not meet its primary endpoint of overall survival in this challenging-to-treat patient population. Therefore, Pexa-Vec will not be further developed as a second-line treatment for HCC but only in the first-line indication." - Rod57 (talk) 18:55, 14 October 2016 (UTC)[reply]

RR gene also deleted

The ribonucleotide reductase gene (aka RNR) may also be deleted - implied by Oct2016 ref, but not mentioned by Cripe2015. - Rod57 (talk) 18:47, 14 October 2016 (UTC)[reply]